US HHS Secretary RFK Jr says FDA is to remove many peptides from category two

This development signals a regulatory shift affecting the use of certain peptides, which may impact the biotech and pharmaceutical sectors significantly. The FDA's decision could influence supply chains and market dynamics as firms adapt to these changes, potentially driving stock volatility in affected equities. Additionally, this could signal a more stringent regulatory environment for drug approvals, which may weigh on investor sentiment.